The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

Follicular lymphoma versus follicular hyperplasia: BCL-2, CD45RA (MT2), immunoglobulin light chain restriction, CD21 and CD35: Small-cell lymphoma: ...

Follicular lymphoma versus follicular hyperplasia: BCL-2, CD45RA (MT2), immunoglobulin light chain restriction, CD21 and CD35: Small-cell lymphoma: ...

9–11 This condition, which appears to be a localized hyperplasia of the normal solitary lymph follicles in the rectal wall, may occur at any location within the rectum and presents as single or ...

Follicular bronchiolitis (FB) has been recognized as a rare, potentially fatal disease that occasionally can be reported concomitantly with antineutrophil cytoplasmic antibody (ANCA)-associated ...

Follicular lymphoma tends to grow slowly and often doesn’t cause symptoms in its early stages. Swollen lymph nodes are typically the first symptom. Learn more.

BACKGROUND: Tertiary lymphoid organs (TLOs) are ectopic lymphoid organs developed in nonlymphoid tissues with chronic inflammation, but little is known about their existence in different types of ...